Inflammasome activation in infected macrophages drives COVID-19 pathology

Sefik, Esen; Qu, Rihao; Junqueira, Caroline; Kaffe, Eleanna; Mirza, Haris; Zhao, Jun; Brewer, J Richard; Han, Ailin; Steach, Holly R.; Israelow, Benjamin; Velazquez, Sofia E.; Chen, Y Grace; Halene, Stephanie; Iwasaki, Akiko; Meffre, Eric; Nussenzweig, Michel; Lieberman, Judy; Wilen, Craig B.; Kluger, Yuval; Flavell, Richard A..
Artículo en Inglés | ARCA | ID: arc-55534

Documentos relacionados

  1. Inflammasome activation in infected macrophages drives COVID-19 pathology.
  2. Specific inhibition of the NLRP3 inflammasome suppresses immune overactivation and alleviates COVID-19 like pathology in mice.
  3. Inflammasome activation in infected macrophages drives COVID-19 pathology.
  4. STING is redundant for host defense and pathology of COVID-19-like disease in mice.
  5. Inflammasome Activation-Induced Hypercoagulopathy: Impact on Cardiovascular Dysfunction Triggered in COVID-19 Patients.
  6. Inflammasome Activation Triggers Blood Clotting and Host Death through Pyroptosis.
  7. N-acetylcysteine Reduces Inflammasome Activation Induced by SARS-CoV-2 Proteins In Vitro.
  8. Mechanisms of endothelial activation, hypercoagulation and thrombosis in COVID-19: a link with diabetes mellitus.
  9. Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation.
  10. Monocytes and Macrophages, Targets of Severe Acute Respiratory Syndrome Coronavirus 2: The Clue for Coronavirus Disease 2019 Immunoparalysis.